CClinicalTrials.gg
CompletedNCT04060576Updated Jan 22, 2020

Post-needling Soreness After Internal Gastrocnemius Muscle Treatment

An interventional study of Dry needling treatment with a thinner needle and Dry needling treatment with a medium-sized needle in Heel Pain Syndrome, sponsored by University of Alcala. Completed at 2 sites in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-01-22.

Sponsored by University of Alcala · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Mechanical hyperalgesia areas, also known as myofascial trigger points, are treated by manual therapy or invasive technics. Dry needling achieves an improvement of the symptomatology in 70% of the subjects, being the acute patients the most benefited. However, bruising, bleeding, pain during treatment or post-needling soreness. Plantar fasciitis is the most common cause of interior heel pain, affects approximately 10% of the general population and is one of the most benefited pathologies in the long term by the application of dry needling The gauge of the needle chosen for the treatment can influence post-needling soreness intensity and pressure pain threshold.

Objective To evaluate the relation between post-needling soreness intensity and needle diameter on the treatment of the most hyperalgesic point of the internal gastrocnemius.

Hypothesis Post-needling soreness intensity and pressure pain threshold depend on needle diameter applied in the treatment of the most hyperalgesic point of the internal gastrocnemius.

Read the detailed description

Intervention:

Two zones are established:

  • Zone 1: where researcher nº 1 controls the data management and sample randomization.
  • Zone 2: where researcher nº 2 locates the most hyperalgesic area and measures pressure point threshold variable and researcher nº 3 performs dry needling puncture.

Researcher nº 1 explains to the subjects how the study works, collects the confidential documents and scores the independent variables (sex, age and BMI). Every subject receives an identification code and is randomly assign to a intervention group (A, B or C) Researcher nº 2 makes delivery of the document where the variables pressure pain threshold and post-needling soreness intensity will be written down. Firstly, the visual analogue scale compliance prior to the intervention is requested. After that, the subject is placed in prone position on the stretcher with a slight knee flexion and the most hyperalgesic area in the internal gastrocnemius of the lower limb with plantar fasciitis is located and marked.

Researcher nº 2 performs the algometry at the most hyperalgesic area (3 measurements with 30 seconds between them), writes down the results of pressure pain threshold variable and leaves the room.

Researcher nº 3 receives a needle from researcher nº 1 ignoring its diameter (colour tab is removed). Firstly, contamination is prevented by disinfection, then, 10 insertions are made at the marked point (the number of local twitch response are counted) and the needle used is thrown in the sanitary waste container. Ischemic compression is performed for 60 seconds followed by an analytical stretch of the internal gastrocnemius for 30 seconds.

Once researcher nº 3 has finished the intervention leaves the room and researcher nº 2 returns to repeat the measurements (post-needling soreness intensity, by filling in VAS, and pressure pain threshold, performing algometry).

Researcher nº 2 reminds the subject to complete VAS at 12, 24, 48 and 72 hours (suggesting setting an alarm) and makes an appointment 48 hours after to perform the third measure of pressure pain threshold variable.

When all the data needed for the study has been collected, researcher nº1 gathers results and exports them for statistical interpretation.

02

Conditions studied

  • Heel Pain Syndrome
03

In context

Lead sponsor

University of Alcala is the lead sponsor of 123 studies on the registry; 36 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age: 18-65.
  • Plantar Fasciitis diagnosis.
  • Presence of hyperalgesic area in the internal gastrocnemius.

Exclusion criteria

Exclusion Criteria:

  • Belenophobia
  • Hypothyroidism Presence of hyperalgesic area in the internal gastrocnemius - Diabetes
  • Lymphedema o lymphatic surgery Muscle diseases
  • Anticoagulant consumption Knee or ankle surgery
  • Analgesic consumption during the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Group A treated with a 16-gauge needle

    Group A is intervened on the gastrocnemius muscle with a 16-gauge needle.

    Procedure: Dry needling treatment with a thinner needle

  • Experimental
    Group B treated with a 25-gauge needle

    Group B is intervened on the gastrocnemius muscle with a 25-gauge needle.

    Procedure: Dry needling treatment with a medium-sized needle

  • Experimental
    Group C treated with a 32-gauge needle

    Group C is intervened on the gastrocnemius muscle with a 32-gauge needle.

    Procedure: Dry needling treatment with a thickest needle

Interventions

  • ProcedureDry needling treatment with a thinner needle

    We will make an application with the dry needling technique with a fine needle on the myofascial trigger points of the gastrocnemius muscle.

  • ProcedureDry needling treatment with a medium-sized needle

    We will make an application with the dry needling technique with a medium-sized needle on the myofascial trigger points of the gastrocnemius muscle.

  • ProcedureDry needling treatment with a thickest needle

    We will make an application with the dry needling technique with the thickest needle on the myofascial trigger points of the gastrocnemius muscle.

06

What researchers measure

Primary outcomes

  1. Post-needling soreness intensity

    The investigators use a Visual Analog Scale (VAS) to determine the intensity of the patient's post-needing pain after and for 72 hours after DN.The VAS is a 100-mm line, oriented horizontally, with one end representing "no pain" and the other end representing "worst pain." Subjects will be asked to rate their current pain with a mark on the scale.

    Time frame: Change From Baseline in Pain Scores on the Visual Analog Scale at 72 hours.

  2. Pressure Pain Threshold

    The PPT serves to determine the sensitivity of hiperalgesic focus. The investigators will done it with one algometer. A lower threshold is a worse result. A higher threshold is a better result.

    Time frame: Change from Baseline Pressure Pain Threshold at 72 hours

07

Study locations

2 sites
  • Grupo Fisioterapia y Dolor
    Alcala de Henares, Madrid 28871, Spain
  • Instituto Fisioterapia y Dolor
    Alcalá De Henares, Madrid 28807, Spain
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04060576
Lead sponsor
University of Alcala
Responsible party
Prof. Dr. Daniel Pecos Martín (Dr. Daniel Pecos Martín, University of Alcala) — Principal investigator
First posted
Aug 19, 2019
Start date
Sep 8, 2019
Primary completion
Dec 16, 2019
Completion
Jan 20, 2020
Last update
Jan 22, 2020

Study contacts

Tomas Gallego-Izquierdo, Dr
study chair · Alcala University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion